Cullinan Associates Inc. Has $793,000 Stake in Gilead Sciences, Inc. $GILD

Cullinan Associates Inc. decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,149 shares of the biopharmaceutical company’s stock after selling 418 shares during the quarter. Cullinan Associates Inc.’s holdings in Gilead Sciences were worth $793,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of GILD. Valeo Financial Advisors LLC raised its position in shares of Gilead Sciences by 26.7% during the second quarter. Valeo Financial Advisors LLC now owns 13,262 shares of the biopharmaceutical company’s stock worth $1,470,000 after acquiring an additional 2,795 shares during the last quarter. Knights of Columbus Asset Advisors LLC grew its stake in Gilead Sciences by 1.5% in the second quarter. Knights of Columbus Asset Advisors LLC now owns 28,863 shares of the biopharmaceutical company’s stock valued at $3,200,000 after acquiring an additional 415 shares during the period. Merit Financial Group LLC boosted its position in shares of Gilead Sciences by 64.1% during the second quarter. Merit Financial Group LLC now owns 47,951 shares of the biopharmaceutical company’s stock worth $5,316,000 after buying an additional 18,722 shares during the period. Simplicity Wealth LLC boosted its position in shares of Gilead Sciences by 158.0% during the second quarter. Simplicity Wealth LLC now owns 11,108 shares of the biopharmaceutical company’s stock worth $1,232,000 after buying an additional 6,802 shares during the period. Finally, Carolina Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 599.3% during the second quarter. Carolina Wealth Advisors LLC now owns 979 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 839 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $112.69 on Monday. Gilead Sciences, Inc. has a twelve month low of $83.98 and a twelve month high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The stock’s 50 day moving average price is $114.34 and its 200-day moving average price is $109.97. The company has a market capitalization of $139.83 billion, a PE ratio of 22.45, a PEG ratio of 0.77 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio is presently 62.95%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock valued at $9,402,130 in the last three months. Corporate insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on GILD. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. UBS Group upped their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a report on Friday, July 25th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Finally, Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a report on Tuesday, August 19th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.